[Remimazolam-Update on Basic Pharmacologic Principles and Clinical Potential]

Overview

Journal Anaesthesiologie

Specialty Anesthesiology

Date 2024 Aug 19

PMID 39158735

Authors

Vera Scheckenbach

Berthold Drexler

Affiliations

Soon will be listed here.

Abstract

In recent years the still relatively new short-acting benzodiazepine remimazolam has been approved and clinically implemented in several countries and regions. Remimazolam is also now approved in the EU and the market launch in Germany is expected in the not too distant future. This is therefore a good point in time to summarize the current evidence for various areas of application, including general anesthesia, sedation and intensive care medicine as well as different dosing schemes.

References

Keam S . Remimazolam: First Approval. Drugs. 2020; 80(6):625-633. DOI: 10.1007/s40265-020-01299-8. View

Birgenheier N, Stuart A, Egan T . Soft drugs in anesthesia: remifentanil as prototype to modern anesthetic drug development. Curr Opin Anaesthesiol. 2020; 33(4):499-505. DOI: 10.1097/ACO.0000000000000879. View

Cohen J, Royston D . Remifentanil. Curr Opin Crit Care. 2001; 7(4):227-31. DOI: 10.1097/00075198-200108000-00003. View

Erhardt P, Woo C, Anderson W, Gorczynski R . Ultra-short-acting beta-adrenergic receptor blocking agents. 2. (Aryloxy)propanolamines containing esters on the aryl function. J Med Chem. 1982; 25(12):1408-12. DOI: 10.1021/jm00354a003. View

Pacofsky G, Stafford J, Cox R, Cowan J, Dorsey Jr G, Gonzales S . Relating the structure, activity, and physical properties of ultrashort-acting benzodiazepine receptor agonists. Bioorg Med Chem Lett. 2002; 12(21):3219-22. DOI: 10.1016/s0960-894x(02)00513-9. View

Kilpatrick G, McIntyre M, Cox R, Stafford J, Pacofsky G, Lovell G . CNS 7056: a novel ultra-short-acting Benzodiazepine. Anesthesiology. 2007; 107(1):60-6. DOI: 10.1097/01.anes.0000267503.85085.c0. View

Chen X, Xin D, Xu G, Zhao J, Lv Q . The Efficacy and Safety of Remimazolam Tosilate Versus Dexmedetomidine in Outpatients Undergoing Flexible Bronchoscopy: A Prospective, Randomized, Blind, Non-Inferiority Trial. Front Pharmacol. 2022; 13:902065. PMC: 9201326. DOI: 10.3389/fphar.2022.902065. View

Kilpatrick G . Remimazolam: Non-Clinical and Clinical Profile of a New Sedative/Anesthetic Agent. Front Pharmacol. 2021; 12:690875. PMC: 8329483. DOI: 10.3389/fphar.2021.690875. View

Chen S, Wang J, Xu X, Huang Y, Xue S, Wu A . The efficacy and safety of remimazolam tosylate versus propofol in patients undergoing colonoscopy: a multicentered, randomized, positive-controlled, phase III clinical trial. Am J Transl Res. 2020; 12(8):4594-4603. PMC: 7476156. View

10.

Drexler B, Grasshoff C, Rudolph U, Unertl K, Antkowiak B . [The GABA(A) receptor family: possibilities for the development of better anesthetics]. Anaesthesist. 2005; 55(3):287-95. DOI: 10.1007/s00101-005-0950-y. View

11.

Choi H, Song I . Review of remimazolam and sedatives in the intensive care unit. Acute Crit Care. 2022; 37(2):151-158. PMC: 9184983. DOI: 10.4266/acc.2022.00619. View

12.

Sancar F, Czajkowski C . Allosteric modulators induce distinct movements at the GABA-binding site interface of the GABA-A receptor. Neuropharmacology. 2010; 60(2-3):520-8. PMC: 3026633. DOI: 10.1016/j.neuropharm.2010.11.009. View

13.

Teixeira M, Brinkman N, Pasternak J, Abcejo A . The Role of Remimazolam in Neurosurgery and in Patients With Neurological Diseases: A Narrative Review. J Neurosurg Anesthesiol. 2023; 36(1):11-19. DOI: 10.1097/ANA.0000000000000917. View

14.

Upton R, Somogyi A, Martinez A, Colvill J, Grant C . Pharmacokinetics and pharmacodynamics of the short-acting sedative CNS 7056 in sheep. Br J Anaesth. 2010; 105(6):798-809. DOI: 10.1093/bja/aeq260. View

15.

Schuttler J, Eisenried A, Lerch M, Fechner J, Jeleazcov C, Ihmsen H . Pharmacokinetics and Pharmacodynamics of Remimazolam (CNS 7056) after Continuous Infusion in Healthy Male Volunteers: Part I. Pharmacokinetics and Clinical Pharmacodynamics. Anesthesiology. 2020; 132(4):636-651. DOI: 10.1097/ALN.0000000000003103. View

16.

Wiltshire H, Kilpatrick G, Tilbrook G, Borkett K . A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. Population pharmacokinetic and pharmacodynamic modeling and simulation. Anesth Analg. 2012; 115(2):284-96. DOI: 10.1213/ANE.0b013e318241f68a. View

17.

Rex D, Bhandari R, Desta T, DeMicco M, Schaeffer C, Etzkorn K . A phase III study evaluating the efficacy and safety of remimazolam (CNS 7056) compared with placebo and midazolam in patients undergoing colonoscopy. Gastrointest Endosc. 2018; 88(3):427-437.e6. DOI: 10.1016/j.gie.2018.04.2351. View

18.

Wesolowski A, Zaccagnino M, Malapero R, Kaye A, Urman R . Remimazolam: Pharmacologic Considerations and Clinical Role in Anesthesiology. Pharmacotherapy. 2016; 36(9):1021-7. DOI: 10.1002/phar.1806. View

19.

Doi M, Hirata N, Suzuki T, Morisaki H, Morimatsu H, Sakamoto A . Safety and efficacy of remimazolam in induction and maintenance of general anesthesia in high-risk surgical patients (ASA Class III): results of a multicenter, randomized, double-blind, parallel-group comparative trial. J Anesth. 2020; 34(4):491-501. DOI: 10.1007/s00540-020-02776-w. View

20.

Yamamoto T, Kurabe M, Kamiya Y . Re-sleeping after reversal of remimazolam by flumazenil. J Anesth. 2021; 35(2):322. DOI: 10.1007/s00540-021-02915-x. View